Latest Breaking News On - Siendo trial - Page 1 : vimarsana.com

Selinexor maintenance generated an improvement in progression-free survival compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer who responded to first-line chemotherapy.

United statesMiami beachNuvation bioGenentech incyteSelinexor xpovioBrian slomovitzGynecologic oncology at mount sinai medical centerPlenary seriesGynecologic oncologyMount sinai medical centerMyriad geneticsOnconova therapeuticsPatients with tp53 wild type advanced or recurrent endometrial cancerSiendo trial